Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for the company’s product, toripalimab injection (subcutaneous injection)…
Read original article on Financial Post →Related news
- BHAV Acquisition Corp II Announces Pricing of $100 Million Initial Public Offering Business Mergers & Acquisitions United States
- Study confirms FireFly on track to be a significant copper producer Business Manufacturing Australia
- Professionals’ Financial – Mutual Funds Inc. announces a change to the management of FDP Canadian Equity Portfolio Economy Markets Canada
- Fired metal shredder worker argued that her alcoholism is a disability Crime & Justice Courts Canada
- Allied Announces Third-Quarter Results Business Corporate Canada
- Hampton Completes Issuance of Shares for Debt Business Corporate Canada
-
DXP Enterprises, Inc. Announces New Share Repurchase Program
Business
Corporate
United States
- Athabasca Oil Reports 2026 Third Quarter Results Business Corporate Canada